In compliance with Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, Lupin has informed that it attached a Press Release on 30th July 2021 regarding acquisition of Southern Cross Pharma, Australia.
The above information is a part of company’s filings submitted to BSE.